

Hikma's Executive Vice Chairman and President of MENA Joins Rakuten Medical's Board of Directors

London, 7 March 2024 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that its Executive Vice Chairman and President of MENA, Mazen Darwazah, has been appointed as a Board Director to Rakuten Medical, Inc. a global biotechnology company developing and commercialising precision, cell targeting therapies based on its proprietary Alluminox™ platform.

In August of last year, Hikma announced signing an exclusive licensing agreement with Rakuten Medical, to commercialise products in Rakuten Medical's pipeline using its photoimmunotherapy Alluminox™ technology platform, in all Hikma's MENA markets. The agreement strengthened Hikma's growing portfolio in oncology and biotechnology bringing a potentially innovative technology to cancer patients in the region.

Mickey Mikitani, Co-CEO of Rakuten Medical, said, "I am delighted to welcome Mazen, a highly experienced global leader, to our board. With his strong operational expertise and track record in driving strategic business decisions that have grown healthcare businesses in the MENA region and globally, I'm sure that Mazen will provide valuable guidance to Rakuten Medical, as the company seeks to grow into a new stage of discovering its full potential as a global biotechnology company."

Commenting on joining Rakuten Medical's Board of Directors, Mazen Darwazah Hikma's Executive Vice Chairman and President of MENA, said: "I'm honoured to join Rakuten Medical's Board of Directors. We're at an important crossroad at Hikma and well-positioned to shape the next chapter of our growth in line with our strategy of moving to provide broader healthcare solutions in MENA. My board appointment will drive synergies and facilitate a closer working relationship with an important partner that shares Hikma's vision of shaping a healthier world."

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal

EVP, Strategic Planning and Global Affairs

Mona Abdallah

Senior Director, MENA Communications

+44 (0)20 7399 2760/ +44 7776 477050

uk-investors@hikma.uk.com

+ 962 6 5802900

MBAbdallah@Hikma.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the



Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About Rakuten Medical, Inc.

Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox[™] platform, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing and tumor necrosis. Alluminox therapies have not yet been approved outside of Japan. Rakuten Medical is committed to its mission to conquer cancer by delivering our innovative treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries, including the United States, where it is headquartered, Japan Taiwan, Switzerland and India. For more information, visit www.rakuten-med.com.